Assay News and Research

RSS

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

Life Technologies expands TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the expansion to its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools designed to detect an additional 241 of the most common mutations in 21 cancer genes.

2 Apr 2012

Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, and Life Technologies Corporation today announced Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays.

2 Apr 2012

Teagasc to coordinate 'National Cheese Research Programme 2015'

Teagasc will coordinate a major new €1.3 million national research project, titled 'National Cheese Research Programme 2015'. Dr Phil Kelly, coordinator of the project, said: "The Irish Cheese Research Consortium (ICRC) embraces the Irish dairy industry's forecast for significant expansion in cheese production, both in overall volume and in specific varieties, over the next 10 years."

31 Mar 2012

Clinical findings from Transgenomic's NuclearMitome Test study on nuclear mitochondrial disorders

Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.

31 Mar 2012

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill.

From NanoString Technologies 31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

Nmnat enzyme plays a critical role in nerve injury

A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection.

31 Mar 2012

ProImmune introduces Special Assay Service

ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.

29 Mar 2012

Affymetrix' GeneChip technology incorporated into Lineagen's FirstStepDx genetic evaluation service

Affymetrix, Inc. and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).

29 Mar 2012

FDA clears BD MAX assay for detecting GBS DNA in Lim Broth cultures

BD announced today the U.S. Food and Drug Administration clearance of the BD MAX Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX System.

From BD (Becton, Dickinson and Company) 29 Mar 2012

EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016.

From Roche Sequencing and Life Science 29 Mar 2012

FDA approves Avioq HTLV-I/II Microelisa System

Avioq, Inc. announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Avioq HTLV-I/II Microelisa System. The test is used for the qualitative detection of antibodies to Human T-Lymphotropic Virus Type I (HTLV-I) and Human T-Lymphotropic Virus Type II (HTLV-II) in human serum or plasma.

29 Mar 2012

USPTO issues patent to Inovio's SynCon H1N1 influenza vaccine

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon universal vaccine related to H1N1 influenza.

26 Mar 2012

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

23 Mar 2012

tAI could predict sensitivity to chemotherapy in patients with triple-negative breast cancer

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin.

23 Mar 2012

MD Anderson, Transgenomic partner to evaluate use of ICE COLD-PCR

Transgenomic, Inc. today announced that it has begun a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the Company's very high sensitivity ICE COLD-PCR mutation detection technology in analysis of DNA isolated from circulating tumor cells (CTCs) in blood samples from patients with advanced cancer.

21 Mar 2012

FDA, Agilent partner to develop new tools for detection of salmonella subtypes

Agilent Technologies Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the U.S. Food and Drug Administration to develop new tools to detect and analyze pathogens in food.

20 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012

Publicly available profile of effects of approved and investigational medicines

The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant testing systems, NIH announced today.

14 Mar 2012